Parkinson's Disease Financial Planning: SSDI Strategy, VA Agent Orange Benefits, and the Cognitive Capacity Window

Nearly 1 million Americans live with Parkinson's disease, and approximately 90,000 new cases are diagnosed each year — most in people in their 60s who are still working, managing retirement savings, and often serving as the primary financial decision-maker for a family. Unlike ALS, Parkinson's is a long disease: 15–20 years from diagnosis to late stage is common. That long arc creates a very different financial planning challenge — not the days-and-weeks urgency of ALS, but a multi-decade set of decisions that must be sequenced correctly. Get them in the wrong order and the cost is real: SSDI filed too late, life insurance closed off before genetic testing, or a power of attorney still unsigned when cognitive decline arrives. This guide covers what patients and families need to act on — and what most general disability-planning resources miss about Parkinson's specifically.

Why Parkinson's financial planning is different from other disability planning

Special-needs financial planning typically involves a parent or sibling planning for a dependent with a lifelong disability. Parkinson's disease planning involves the person themselves — often still working, still the family's primary financial decision-maker — planning for their own progressive disability across three distinct phases:

• Phase 1 — Early PD (years 1–10, approximately): Mild motor symptoms, typically controlled with medication. Most patients continue working. Financial priorities in this phase: SSDI strategy, life and long-term disability insurance review, beneficiary designation audit, and document execution — before the cognitive risk window opens.
• Phase 2 — Motor fluctuation phase (years 5–15): On/off periods, dyskinesias, increasing care needs. May involve deep brain stimulation (DBS) surgery or advanced infusion therapies. SSDI is active; Medicare coverage becomes central. Equipment cost planning and in-home care begin.
• Phase 3 — Advanced PD (years 10–20+): Significant motor disability, possible dementia. SNT-level financial coordination if SSI is relevant; trustee and POA decisions are now operational, not theoretical. Caregiver burden is at its peak.

Two unique planning factors distinguish PD from most other conditions on this site:

• Genetic PD creates an insurance urgency analogous to Huntington's disease. Known genetic mutations (LRRK2, GBA, PINK1) drive familial PD in a meaningful share of cases. GINA does not protect life insurance, disability insurance, or long-term care insurance. Family members who have not been tested must secure those policies before genetic testing is done — after a positive test, coverage may be denied or rated unaffordable.
• Standard Parkinson's disease does NOT qualify for SSA's Compassionate Allowances fast-track. Unlike ALS, Huntington's, or the Parkinson's-plus syndromes (PSP, MSA, CBD), idiopathic PD goes through the standard SSDI evaluation process — typically 3–6 months. Families who assume the fast-track exists are in for a surprise when the SSDI application takes months rather than days.

SSDI: the standard path under Listing 11.06

Standard Parkinson's disease is not on the Compassionate Allowances list

SSA's Compassionate Allowances program processes approximately 300 conditions in ~10 days because the diagnoses are inherently so severe that standard evaluation is unnecessary. Parkinson's disease (idiopathic, typical) is not on this list.¹ Applicants proceed through the standard five-step evaluation against Blue Book Listing 11.06.

The practical implication: file early, while still working if possible, because the initial decision takes 3–6 months. If denied, the appeal process can add another 6–18 months. The SSA processes PD applications on the same timeline as any other chronic condition. Do not wait for symptoms to progress before filing — file when you first stop working due to PD, or when motor symptoms substantially limit your ability to work.

How Blue Book Listing 11.06 works

To qualify automatically under Listing 11.06 (Parkinsonian syndrome), symptoms must persist despite at least 3 consecutive months of prescribed treatment, AND meet either criterion A or B:²

• Criterion A: Disorganization of motor function in two extremities resulting in extreme limitation in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities.
• Criterion B: Marked limitation in physical functioning, AND marked limitation in at least one of: understanding, remembering, or applying information; OR adapting or managing oneself.

The key documentation elements: neurologist's notes demonstrating persistent motor dysfunction, functional status assessments, a log of medications tried and their response, and ideally observations from a movement disorder specialist (a neurologist sub-specializing in PD — fewer than 1,500 practice in the US).

RFC approach for those who don't meet 11.06 exactly

Many PD patients have significant functional limitations that don't fit the literal 11.06 criteria — slower movement, tremor affecting fine motor work, fatigue, or cognitive slowing — without the "extreme limitation" language in criterion A. For these applicants, SSA's Residual Functional Capacity (RFC) assessment determines whether the combination of limitations prevents all full-time employment. A well-documented RFC with detailed observations from the movement disorder specialist, occupational therapist, and treating neurologist can support approval even without meeting Listing 11.06 directly.

The 5-month waiting period and 24-month Medicare gap apply to PD

Unlike ALS (which eliminated both waiting periods entirely), Parkinson's disease follows the standard SSDI rules:

• 5-month elimination period: SSDI benefits don't begin until month 6 of established disability onset. A patient who stops working in January 2026 receives no SSDI for that month or the four that follow; the first check covers June 2026.
• 24-month Medicare waiting period: Medicare begins 24 months after SSDI entitlement starts, not at the time of SSDI award. During those 24 months, the patient needs coverage for potentially significant costs: neurologist visits, DBS evaluation workups, specialty medications. The standard bridge: the COBRA disability extension (29 months of COBRA at up to 102% of the group premium). For a PD patient in their 60s paying $800–$1,500/month for COBRA, this bridge costs $20,000–$43,000 over the gap period.

For PD patients who have VA disability coverage (discussed below), the VA healthcare system can serve as a primary or supplemental bridge during the Medicare waiting period at no additional cost.

Parkinson's-plus syndromes: the CAL fast-track does apply

Three neurological conditions that are frequently initially misdiagnosed as Parkinson's disease are on the SSA Compassionate Allowances list — meaning they qualify for ~10-day SSDI decisions once the correct diagnosis is documented:

Why this matters: patients diagnosed with PD who later receive a corrected diagnosis of PSP, MSA, or CBD should immediately notify SSA. If a PD SSDI application is pending and the neurologist updates the diagnosis to a CAL condition, the application can be reclassified for expedited processing. Families who receive a Parkinson's-plus diagnosis should assume the CAL route and file with the confirmed specialist diagnosis in hand.

VA benefits for veterans with Parkinson's disease

Agent Orange exposure is linked to Parkinson's disease under published VA regulations — and the veteran compensation benefit this creates is one of the most underutilized resources in the entire PD community.

The 38 CFR 3.309(e) Agent Orange presumptive

Under 38 CFR 3.309(e), Parkinson's disease is a presumptive service-connected condition for veterans who served in the Republic of Vietnam between January 9, 1962, and May 7, 1975.³ Presumptive means the veteran does not need to prove a direct connection between their Vietnam service and their PD diagnosis — the connection is assumed by law. Requirements: qualifying Vietnam service record + current PD diagnosis from a medical provider. That's it.

In 2026, the VA also recognizes "Parkinsonism" — Parkinson's-like motor features that don't meet full idiopathic PD diagnostic criteria — as a newer Agent Orange presumptive condition, extending the benefit to a broader range of veterans with motor symptoms linked to Agent Orange exposure.⁴

100% permanent and total VA rating

Veterans with PD under the Agent Orange presumptive typically receive a 100% permanent and total (P&T) disability rating, the highest level, which cannot be reduced and carries full compensation, VA healthcare, and dependent benefits. The 2026 monthly rates:

VA compensation has no income or asset test and does not interfere with SSDI (the two programs pay independently). A veteran with PD can receive full VA compensation, full SSDI, and any private pension simultaneously. The VA also covers DBS surgery at VA medical centers, neurologist and movement disorder specialist visits, and specialty medications for PD through the VA formulary.

Aid and Attendance for advanced PD

As PD progresses, veterans who require regular aid and attendance — assistance with daily activities, regular nursing care, or who cannot safely be left alone — may qualify for Special Monthly Compensation (SMC) levels that substantially exceed the standard 100% rate. SMC-L (aid and attendance) begins at approximately $4,900/month in 2026 for a single veteran. For veterans requiring a higher level of care, SMC-R1 and R2 rates can exceed $11,000/month.

VA Caregiver Support Program for PD spouses

Spouses or adult children who provide substantial caregiver support to a 100% P&T veteran with PD may qualify for the Primary Family Caregiver Program: a monthly stipend ($600–$3,800+/month depending on care hours and tier), CHAMPVA health coverage, respite care, and caregiver training. Apply through the VA social work team — do not wait for PD to reach an advanced stage, as the application and approval process can take several months.

Genetic Parkinson's disease and the GINA insurance gap

Approximately 10–15% of all Parkinson's cases have a clearly identified genetic cause. The most common genetic risk factors:

• GBA (glucocerebrosidase gene) mutations: The most common PD genetic risk factor — GBA variants are found in 5–15% of PD patients across populations and confer a 5–15× increased lifetime risk of developing PD. GBA mutations also accelerate cognitive decline — GBA-positive PD patients reach dementia faster on average than idiopathic PD patients.
• LRRK2 (leucine-rich repeat kinase 2) mutations: Found in ~1–4% of all PD patients. Autosomal dominant; penetrance is incomplete (not every carrier develops PD). The most common familial PD mutation in European and Ashkenazi Jewish populations.
• PINK1 and PARKIN mutations: Autosomal recessive; associated with early-onset PD (before age 50). Slower progression than idiopathic PD in some studies.

The planning implication is identical to Huntington's disease: GINA does not protect life insurance, long-term disability insurance, or long-term care insurance from genetic discrimination.⁵ GINA covers only health insurance and employment. A family member with a LRRK2 or GBA mutation who tests positive can legally be denied life insurance or charged rated premiums. The sequencing rule:

1. Secure life insurance and long-term disability insurance while healthy and before any genetic testing is done.
2. Then, if desired, pursue genetic testing — now the insurance status is locked in and the test results cannot retroactively affect it.

This matters not only for the PD patient but for their adult children who may carry LRRK2 or GBA variants. A 40-year-old child of a GBA-positive PD parent who pursues genetic testing before buying life insurance is taking a meaningful financial risk.

Deep brain stimulation: cost planning, battery replacement, and Medicare coverage

Deep brain stimulation (DBS) is the most common surgical treatment for PD when medications stop providing adequate control of motor symptoms. The financial planning involves not just the initial surgery but a recurring replacement schedule that many families are unprepared for.

Initial DBS costs

In the United States, total costs for DBS — including the neurostimulator device, bilateral lead implantation, and initial programming — range from approximately $70,000 to $110,000 for a bilateral procedure (both sides of the brain), with some centers billing higher.⁶ Unilateral procedures (one side) run approximately $35,000–$60,000. Medicare Part B covers DBS for approved indications (including PD with motor complications) and pays 80% of the approved amount after the Part B deductible; the remaining 20% is coinsurance. With Medigap Plan G, the Part B coinsurance is eliminated. For under-65 PD patients on Medicare via SSDI, Medigap access varies by state — see the Medicare for people with disabilities guide for details on states that mandate Medigap access.

Battery replacement: the recurring cost families don't anticipate

Standard (non-rechargeable) DBS neurostimulator batteries deplete in approximately 2–5 years depending on stimulation settings. Each replacement requires a minor outpatient surgery under local anesthesia to access the implanted pulse generator. Replacement device and procedure costs run $20,000–$50,000, recurring throughout the patient's life. Rechargeable battery systems extend the device life to 9–15 years but require the patient to charge the device daily via an external charging wand — cognitive or motor limitations in advanced PD can make daily charging difficult.

A 65-year-old who receives DBS and lives to 85 may require 3–6 battery replacement procedures over their lifetime. This should be budgeted explicitly in any long-term financial plan. SNT distribution language for PD patients should specifically authorize DBS battery replacement and neurostimulator upgrades as covered expenses.

Post-implant programming

After DBS implantation, neurologist programming visits occur frequently in the first year (typically 4–8 visits) to optimize stimulation parameters, then less often annually. Each programming visit is typically billed as an outpatient neurology visit. With Medicare, the patient's share after Part B coinsurance or Medigap runs $0–$200 per visit. Access to a movement disorder specialist who programs DBS systems is an underappreciated consideration — fewer than 1,500 movement disorder specialists practice in the US, and rural patients may travel 2–4 hours for programming visits.

Advanced therapies for motor fluctuations

When standard oral levodopa causes problematic on/off fluctuations and DBS is not appropriate or not desired, two device-based infusion options exist for advanced PD:

Duopa (carbidopa-levodopa enteral suspension)

Duopa delivers carbidopa-levodopa as a continuous intestinal gel infusion via a surgically-placed percutaneous endoscopic gastrojejunostomy (PEG-J) tube connected to an external pump. Approved by the FDA in 2015. The PEG-J tube placement is itself a procedural cost and carries risks of tube dislodgment and site infection. Duopa is a specialty-tier drug; the WAC is not publicly disclosed in standard databases, but it is a high-cost specialty therapy with manufacturer patient assistance available through myAbbVie Assist. Medicare Part D provides the $2,100/year out-of-pocket cap (2026) for those on Part D, significantly limiting annual patient cost once the cap is met.

Vyalev (foscarbidopa and foslevodopa)

Vyalev, approved by the FDA on October 17, 2024, delivers a subcutaneous (under-the-skin) continuous infusion — no surgery required, unlike Duopa's PEG-J tube.⁷ It represents a meaningful advance in accessibility for patients who cannot or will not undergo PEG-J placement. Vyalev is dispensed via specialty pharmacy and is covered under Medicare Part D (subject to the $2,100/year OOP cap in 2026 for Part D enrollees). Manufacturer assistance and copay support programs are available through AbbVie.

The practical financial planning point for both therapies: Medicare Part D's $2,100 annual out-of-pocket cap (2026, per the IRA) means that even very expensive specialty infusion drugs have a capped patient liability for Medicare-enrolled PD patients. For PD patients not yet on Medicare — during the 24-month waiting period — the bridging coverage plan must account for potentially substantial specialty drug costs. Medicaid provides access for income-qualifying PD patients, and Section 1619(b) Medicaid protection allows SSI recipients who work to keep Medicaid even when earned income exceeds the SGA threshold (see SSI work incentives guide).

The cognitive capacity planning window

This is the section most PD patients and families delay too long, and it is the most consequential planning gap in Parkinson's disease financial management.

Parkinson's disease dementia (PDD) develops in approximately 50–75% of PD patients over the course of the illness.⁸ The mean time from PD motor symptom onset to dementia diagnosis is approximately 10 years — but this varies enormously. GBA-positive PD patients reach dementia faster. Patients with Lewy body dementia (DLB), a closely related condition that begins with cognitive symptoms rather than motor symptoms, may experience significant cognitive impairment early. Even in idiopathic PD without formal dementia, executive function, processing speed, and visuospatial ability decline over years — affecting the person's ability to manage finances, execute legal documents, or participate in complex planning discussions.

The window in which a PD patient can fully and meaningfully direct their own financial and legal plan is wide at diagnosis but narrows over time in a way that is impossible to predict precisely. The rule: do not defer legal and financial planning to Phase 2 or 3 — do it in Phase 1, early, while the patient is the architect of every decision.

Five documents that must be executed while cognitive capacity is intact

1. Durable financial power of attorney (DPOA): Names who manages finances, investments, government benefits applications, and real estate when the patient can no longer do so. Must be effective immediately (not springing) and durable (effective upon incapacity). Review that it explicitly covers retirement account management, trust amendments, and gifting authority if those are relevant — some states require enumerated powers for these acts.
2. Healthcare power of attorney / healthcare proxy: Names the agent who makes medical decisions when the patient cannot communicate clearly. Choose someone who understands the patient's values around advanced interventions.
3. Advance directive / living will: Documents specific wishes for life-sustaining treatment. For PD, this should address artificial nutrition and hydration during a swallowing crisis (dysphagia is common in advanced PD), ventilator use, and resuscitation. Vague directives create family conflict in crises.
4. POLST form (Physician Orders for Life-Sustaining Treatment): A physician-signed medical order that is enforceable by emergency responders and hospital staff. Complete it with the movement disorder specialist or neurologist, not at the time of a hospitalization when urgency may limit thoughtful discussion.
5. Updated will and beneficiary designations: All retirement accounts, life insurance, and bank accounts must reflect current beneficiary intentions. If any beneficiary is receiving SSI or Medicaid, their designation must name a Special Needs Trust — a direct inheritance or life insurance payout to an SSI beneficiary destroys their benefits immediately. See the IRA and 401(k) beneficiary planning guide for how to correctly structure these designations.

Trustee succession if the PD patient currently serves as trustee or guardian

PD patients who currently serve as trustee of a Special Needs Trust for a disabled child or sibling — or as guardian — must review successor designation in the trust document and, if guardianship is involved, may need to file a petition for successor guardian with the probate court while still able to provide testimony about the successor's suitability and the ward's needs.

Special Needs Trust considerations for Parkinson's disease

The SNT scenarios in PD planning come from two directions: the PD patient as estate planner for a disabled dependent, and the PD patient themselves as a potential SNT beneficiary.

Third-party SNT for a disabled dependent

If the PD patient is the parent or sibling of someone receiving SSI or Medicaid, their estate plan must route any inheritance or life insurance payout through a third-party Special Needs Trust — not directly to the person with a disability. Given the cognitive decline risk in PD, this correction of wills, beneficiary designations, and trust documents must be made in Phase 1 — not "whenever we get around to it." A direct bequest to an SSI beneficiary from a PD patient who delays this task until capacity is gone may be uncorrectable. See the estate planning for special needs families guide.

First-party SNT when the PD patient receives a windfall on Medicaid

If a PD patient on Medicaid (lower-income, early-phase PD patients may qualify) receives a direct inheritance, personal injury settlement, or large lump sum, that money must be directed into a first-party d4A Special Needs Trust before it is received — or Medicaid disqualification results from the resource exceeding the $2,000 SSI limit. Veterans who receive large VA retroactive back-pay awards while on Medicaid should have a first-party SNT framework in place before the award arrives. See the first-party vs third-party SNT guide.

SNT distribution language for PD beneficiaries

An SNT whose beneficiary has PD should explicitly authorize, as non-ISM supplemental expenses:

• Movement disorder specialist fees not covered by Medicare (second opinions, remote programming visits)
• DBS neurostimulator battery replacement surgery and device upgrades
• Advanced therapy infusion supplies (pump consumables, site supplies for subcutaneous therapy)
• Physical, occupational, and speech therapy (above Medicare-covered amounts)
• Exercise programs, tango dancing, and aquatic therapy (evidence-supported PD interventions)
• Home modifications for falls prevention: grab bars, stair lifts, roll-in showers, alert systems
• Transportation to specialist appointments and therapy (not ISM under 2024 SSA food rule)
• Respite care for spouse caregivers
• Private-hire aides for ADL assistance exceeding covered home health hours

ABLE accounts for Parkinson's disease patients

ABLE account eligibility requires that the qualifying disability had an onset before age 46 (expanded from age 26 by the ABLE Age Adjustment Act, effective January 2026).⁹

The practical implication for PD:

• Most PD patients (typical onset ~60): NOT ABLE-eligible. The vast majority of idiopathic PD patients were diagnosed well after age 46 — meaning their disability onset, by SSA's functional definition, occurred after the cutoff.
• Early-onset PD (diagnosed before age 50) — approximately 10% of PD cases: May qualify if the disability can be documented as functionally significant before age 46. The onset date used is when the disability substantially began limiting function, not necessarily the clinical diagnosis date.
• Young-onset PD (diagnosed before age 40): Most likely to qualify. These patients typically have PINK1 or PARKIN mutations and experience a slower disease course — but ABLE eligibility may still be possible and provides a flexible spending vehicle for disability-related expenses up to $100,000 in the account before SSI is affected.

For eligible early-onset PD patients on SSI, ABLE accounts allow up to $20,000/year in contributions (2026), tax-free growth, and flexible spending on qualified disability expenses — without the trustee oversight required for SNT distributions. Working early-onset PD adults can contribute an additional $15,650 from earned income via the ABLE-to-Work provision. See the ABLE account 2026 guide for the full eligibility rules.

Section 1619(b) for working early-onset PD adults on SSI

For the subset of PD patients who are on SSI (typically early-onset, lower-income patients with limited work history), Section 1619(b) Medicaid protection allows continued Medicaid eligibility even when earned income exceeds the SSI payment standard — up to a state-specific threshold that ranges from approximately $20,000 to $75,000+ per year. This protection is critical for patients who depend on Medicaid for advanced PD therapies or for the SSDI 24-month Medicare bridge. See the SSI work incentives guide.

Caregiver financial planning for PD spouses

Parkinson's disease caregiving is a multi-decade commitment that intensifies gradually. The financial impact on the spouse-caregiver compounds over time in ways that are easy to underestimate at diagnosis:

• Reduced workforce participation: PD spouses frequently reduce hours or exit the workforce in Phase 2 or 3. Each year of reduced employment shrinks their own Social Security retirement benefit. A spouse who exits the workforce at 58 to care full-time and re-enters at 68 (if at all) may have a retirement benefit 25–40% lower than a continuous-work scenario. Model this gap explicitly — it is often the largest single financial exposure in long-duration PD planning.
• No federal job protection after FMLA: Federal FMLA provides 12 weeks of unpaid, job-protected leave per year for a spouse's serious health condition. Several states (California, New York, New Jersey, Washington, Connecticut, Oregon, Colorado, Massachusetts, Delaware, Maryland, Minnesota) have paid family leave programs. But FMLA is episodic — it doesn't protect a caregiver who needs to reduce to part-time for years.
• Caregiver's own LTC risk: Spouses of PD patients who spend years in caregiving roles face their own elevated risk of health deterioration. The financial plan should explicitly model what happens if both members of the couple need long-term care — which means the caregiver's own life insurance and LTC insurance must be in force, not just the PD patient's.
• VA Caregiver Support Program (veterans): As described above, the primary family caregiver of a 100% P&T veteran with PD may qualify for a monthly stipend and CHAMPVA healthcare coverage. This is the most substantial financial caregiver benefit available for this group and is dramatically underutilized.

Priority action checklist for PD patients and families

1. If a Vietnam-era veteran, file VA Agent Orange claim now — PD is a presumptive condition; $3,938.58+/month from date of filing; contact a Veterans Service Organization (VSO) for expedited submission assistance
2. Review life insurance and long-term disability coverage immediately — before any genetic testing is done; if face value is inadequate, explore new coverage while health permits underwriting
3. Execute all legal documents in Phase 1 — DPOA, healthcare proxy, advance directive, POLST; do not defer until Phase 2 or cognitive concerns appear
4. Audit all beneficiary designations — any disabled family member named directly on IRAs, 401(k)s, life insurance, or bank TODs must be re-directed to their Special Needs Trust
5. File SSDI when you stop working — remember the 5-month elimination period: file immediately at job stop, not after symptoms worsen; gather movement disorder specialist notes and functional assessments first
6. Plan the 24-month Medicare bridge — COBRA disability extension for 29 months; model monthly cost and factor into income replacement plan; VA healthcare eliminates this gap for eligible veterans
7. Discuss DBS candidacy with your movement disorder specialist — if DBS may be in your future, understand the battery replacement cost cycle and plan for it before it's needed
8. Check ABLE eligibility if early-onset — disability onset before age 46 qualifies; flexible spending tool above the SNT for eligible patients
9. Review SNT trustee succession — if PD patient currently serves as trustee for a disabled dependent, update the successor designation chain now
10. Engage the three-professional team — special needs financial planner (if disabled dependents are involved), estate attorney (for POA and trust documents), and a VA-accredited claims agent or VSO (for veterans)

Sources

1. Social Security Administration — Complete List of Compassionate Allowances Conditions. The current CAL list (updated August 2025) includes Progressive Supranuclear Palsy, Multiple System Atrophy, and Corticobasal Degeneration as CAL conditions. Idiopathic Parkinson's disease does not appear on this list and proceeds through standard SSA evaluation under Listing 11.06.
2. Social Security Administration Blue Book — 11.00 Neurological Disorders (Adult). Listing 11.06 (Parkinsonian syndrome) criteria: disorganization of motor function in two extremities resulting in extreme limitation in standing, balancing, or upper extremity use (criterion A); or marked limitation in physical functioning and marked limitation in one mental area (criterion B). Both must persist despite 3 consecutive months of prescribed treatment.
3. U.S. Department of Veterans Affairs — Veterans' Diseases Associated with Agent Orange. Parkinson's disease is listed as a presumptive service-connected condition for veterans with qualifying Agent Orange exposure under 38 CFR 3.309(e). Veterans diagnosed with PD who served in the Republic of Vietnam during the qualifying period are presumed service-connected and eligible for VA disability compensation.
4. VA Claims Mastery — Agent Orange Presumptive Conditions Guide (2026). Documents that "Parkinsonism" was added as a newer Agent Orange presumptive condition in 2026, in addition to the existing Parkinson's disease presumptive that has been in place for Vietnam-era veterans. Distinguishes Parkinsonism (Parkinson's-like motor features) from full idiopathic PD diagnosis.
5. National Human Genome Research Institute — About the Genetic Information Nondiscrimination Act (GINA). GINA Title I prohibits discrimination in health insurance based on genetic information. GINA Title II prohibits genetic discrimination in employment. GINA does NOT apply to life insurance, disability insurance, or long-term care insurance — insurers may use genetic information in underwriting decisions for these products.
6. Bookimed — Deep Brain Stimulation Cost Comparison: US and International. US bilateral DBS surgery total cost (device, implantation, initial programming): approximately $70,000–$110,000 as of April 2026. Unilateral procedures run $35,000–$60,000. Medicare Part B covers DBS for approved indications; 20% coinsurance applies without Medigap supplemental coverage.
7. AbbVie Press Release — U.S. FDA Approves VYALEV (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease (October 17, 2024). FDA approved the first and only subcutaneous 24-hour continuous infusion levodopa-based therapy for treatment of motor fluctuations in adults with advanced PD. Non-surgical delivery route distinguishes Vyalev from Duopa (intestinal gel requiring PEG-J tube placement). Medicare Part D coverage applies.
8. Parkinson's Foundation — Understanding Parkinson's Statistics. Approximately 1 million Americans live with PD; 90,000 new diagnoses annually. Parkinson's disease dementia (PDD) develops in a majority of PD patients over the long disease course, with studies estimating prevalence at 50–75% in long-duration PD. GBA-positive patients typically experience earlier cognitive decline than idiopathic PD patients.
9. IRS Notice 2021-59 and ABLE Age Adjustment Act (January 2026). The ABLE Age Adjustment Act (enacted December 2022, effective January 1, 2026) expanded ABLE account eligibility from disability onset before age 26 to disability onset before age 46. Contribution limit: $20,000/year (2026) from all sources, with an additional $15,650 available for working beneficiaries under ABLE-to-Work provisions. Account balance up to $100,000 is excluded from SSI resource calculation.

Rules and rates verified against 2026 SSA, VA, and Medicare standards. SSA Listing 11.06 criteria per Blue Book 11.00 (SSA.gov). CAL list current as of August 2025 (PSP, MSA, CBD on CAL; idiopathic PD not on CAL). VA 100% P&T rate $3,938.58/month for single veteran (2026, 2.8% COLA effective December 1, 2025). DBS bilateral cost $70,000–$110,000 (2026 US market). Medicare Part D OOP cap $2,100/year (2026, per Inflation Reduction Act). ABLE eligibility: disability onset before age 46 (ABLE Age Adjustment Act, effective January 2026). GINA per 42 U.S.C. § 2000ff et seq. — does not cover life, disability, or long-term care insurance. SSI resource limit $2,000 individual (unchanged since 1989).